PL2722044T3 - Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo - Google Patents

Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Info

Publication number
PL2722044T3
PL2722044T3 PL14151678T PL14151678T PL2722044T3 PL 2722044 T3 PL2722044 T3 PL 2722044T3 PL 14151678 T PL14151678 T PL 14151678T PL 14151678 T PL14151678 T PL 14151678T PL 2722044 T3 PL2722044 T3 PL 2722044T3
Authority
PL
Poland
Prior art keywords
vomiting
compositions
centrally mediated
treating
nausea
Prior art date
Application number
PL14151678T
Other languages
English (en)
Inventor
Fabio Trento
Sergio Cantoreggi
Giorgia Rossi
Roberta Canella
Daniele Bonadeo
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2722044(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PL2722044T3 publication Critical patent/PL2722044T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL14151678T 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo PL2722044T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14

Publications (1)

Publication Number Publication Date
PL2722044T3 true PL2722044T3 (pl) 2017-08-31

Family

ID=43608757

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14151678T PL2722044T3 (pl) 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL10805301T PL2361090T3 (pl) 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL14151683T PL2722045T3 (pl) 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL10805301T PL2361090T3 (pl) 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo
PL14151683T PL2722045T3 (pl) 2009-11-18 2010-11-18 Kompozycje do leczenia nudności i wymiotów mediowanych ośrodkowo

Country Status (39)

Country Link
US (1) US20230263799A1 (pl)
EP (3) EP2727590B1 (pl)
JP (1) JP5890780B2 (pl)
KR (1) KR101615108B1 (pl)
CN (6) CN102655864A (pl)
AP (1) AP3083A (pl)
AU (1) AU2010320598B2 (pl)
BR (1) BR112012011485B1 (pl)
CA (1) CA2778301C (pl)
CL (1) CL2012001276A1 (pl)
CO (1) CO6551693A2 (pl)
CR (1) CR20120216A (pl)
CU (1) CU24048B1 (pl)
CY (1) CY1118062T1 (pl)
DK (2) DK2722045T3 (pl)
DO (1) DOP2012000138A (pl)
EA (1) EA026815B1 (pl)
EC (1) ECSP12011907A (pl)
ES (4) ES2559475T3 (pl)
GE (1) GEP20156226B (pl)
GT (1) GT201200156A (pl)
HK (2) HK1214148A1 (pl)
HR (3) HRP20140759T1 (pl)
HU (1) HUE029677T2 (pl)
IL (1) IL219576A (pl)
LT (1) LT2722045T (pl)
MA (1) MA33810B1 (pl)
MX (1) MX2012005347A (pl)
MY (1) MY159393A (pl)
NI (1) NI201200090A (pl)
NZ (1) NZ599439A (pl)
PE (1) PE20121483A1 (pl)
PL (3) PL2722044T3 (pl)
PT (2) PT2722045T (pl)
RS (2) RS55206B1 (pl)
SI (2) SI2361090T1 (pl)
SM (1) SMT201400112B (pl)
TN (1) TN2012000170A1 (pl)
WO (1) WO2011061622A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
MY159393A (en) 2009-11-18 2016-12-30 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting
NO2729147T3 (pl) * 2011-07-04 2018-02-03
PL2744497T3 (pl) * 2011-10-18 2016-10-31 Terapeutyczne połączenia netupitantu i palonosetronu
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN111343981A (zh) * 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
AU2019215802A1 (en) * 2018-02-02 2020-07-23 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI98367C (fi) 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
PT1394150E (pt) 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
DK1303490T3 (da) 2000-07-14 2008-08-25 Hoffmann La Roche N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
EP1349541B1 (en) 2000-12-14 2006-10-04 F. Hoffman-la Roche AG Self emulsifying lipid matrix (selm)
DE10393729T5 (de) 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
MX2008010899A (es) 2006-02-23 2008-11-27 Pfizer Ltd Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4.
MX2009004461A (es) * 2006-10-24 2009-09-16 Helsinn Healthcare Sa Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada.
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
MX2010006854A (es) * 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
MY159393A (en) 2009-11-18 2016-12-30 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting

Also Published As

Publication number Publication date
CY1118062T1 (el) 2017-06-28
CN106421793B (zh) 2023-06-16
AP3083A (en) 2015-01-31
RS53491B1 (en) 2015-02-27
CA2778301A1 (en) 2011-05-26
HRP20170419T1 (hr) 2017-06-02
JP2013511507A (ja) 2013-04-04
BR112012011485A2 (pt) 2018-04-03
EP2727590B1 (en) 2015-10-21
GT201200156A (es) 2014-03-27
CA2778301C (en) 2016-06-14
HK1214147A1 (zh) 2016-07-22
WO2011061622A1 (en) 2011-05-26
CU20120078A7 (es) 2012-10-15
SI2722045T1 (sl) 2017-02-28
ECSP12011907A (es) 2012-10-30
EP2722044B1 (en) 2017-01-04
AP2012006278A0 (en) 2012-06-30
MA33810B1 (fr) 2012-12-03
DK2722045T3 (en) 2016-10-24
EA026815B1 (ru) 2017-05-31
HUE029677T2 (hu) 2017-03-28
CN102655864A (zh) 2012-09-05
GEP20156226B (en) 2015-01-26
SMT201400112B (it) 2014-11-10
ES2494015T3 (es) 2014-09-12
PL2361090T3 (pl) 2014-10-31
PE20121483A1 (es) 2012-12-02
EA201290356A1 (ru) 2012-12-28
CN104856999A (zh) 2015-08-26
EP2727590A1 (en) 2014-05-07
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
CR20120216A (es) 2012-07-24
PT2361090E (pt) 2014-09-03
KR101615108B1 (ko) 2016-05-12
CO6551693A2 (es) 2012-10-31
AU2010320598A1 (en) 2012-06-14
PT2722045T (pt) 2016-10-18
CN106512010A (zh) 2017-03-22
CN107050455A (zh) 2017-08-18
CN104856998A (zh) 2015-08-26
PL2722045T3 (pl) 2017-03-31
BR112012011485B1 (pt) 2021-06-29
HRP20140759T1 (hr) 2014-10-24
AU2010320598B2 (en) 2016-06-16
DOP2012000138A (es) 2012-11-15
NZ599439A (en) 2014-06-27
MX2012005347A (es) 2012-08-03
RS55206B1 (sr) 2017-01-31
JP5890780B2 (ja) 2016-03-22
CN107050455B (zh) 2020-09-29
ES2595077T3 (es) 2016-12-27
CU24048B1 (es) 2014-12-26
ES2559475T3 (es) 2016-02-12
LT2722045T (lt) 2016-09-26
SI2361090T1 (sl) 2014-09-30
IL219576A0 (en) 2012-06-28
US20230263799A1 (en) 2023-08-24
MY159393A (en) 2016-12-30
TN2012000170A1 (en) 2013-12-12
DK2361090T3 (da) 2014-08-25
NI201200090A (es) 2012-11-13
HRP20161277T1 (hr) 2016-11-18
ES2623503T3 (es) 2017-07-11
KR20120101456A (ko) 2012-09-13
IL219576A (en) 2017-08-31
CN106421793A (zh) 2017-02-22
EP2361090B1 (en) 2014-05-21
HK1214148A1 (zh) 2016-07-22
CL2012001276A1 (es) 2012-12-07

Similar Documents

Publication Publication Date Title
HK1214147A1 (zh) 用於治療中樞介導的噁心及嘔吐的組合物及方法
IL245734A0 (en) Methods and preparations to prevent abuse
EP2473042A4 (en) METHODS AND COMPOSITIONS FOR DESTROYING BIOFILM USING COMPOUNDS DERIVED FROM CHITOSAN
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
IL215932A0 (en) Compositions and methods for treating burns
EP2722045A3 (en) Compositions for treating centrally mediated nausea and vomiting
GB0903299D0 (en) Composition and methods
GB0912468D0 (en) Composition and method
EP2490536A4 (en) COMPOSITION AND METHOD
EP2294198A4 (en) METHODS AND COMPOSITIONS FOR ENHANCING PLANTS
GB0901494D0 (en) Compositions and Methods
EP2393506A4 (en) METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
PL2263454T3 (pl) Kompozycja uzdatniająca
IL217764A0 (en) Methods and compositions for treating leukemia
EP2501672A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS
GB0901667D0 (en) Composition and method
ZA201203174B (en) Compositions for treating centrally mediated nausea and vomiting
HK1166017A1 (en) Compositions and methods for causing neurite outgrowth
GB0912714D0 (en) Composition and process
IL219215A0 (en) Compositions and methods for treating aspergillosis
GB0908498D0 (en) Compositions and methods
GB0907616D0 (en) Methods and compositions
GB0909720D0 (en) Compositions and methods